Nancy Yu has always found herself at the intersection of scientific research and bringing new science to the market. She sees a world where patients and drug developers can be brought closer together, as their interests in realizing new drug treatments are most directly aligned. Previous to starting RDMD, she led Corporate Development and Special Projects at 23andme, worked closely with consumer healthcare companies at HIG Capital, and was a biotech investment banker on Wall Street before that. Nancy holds a dual degree in biology and finance from the University of Pennsylvania and the Wharton School of Business.